Rona Smith talks about the findings from the RITAZAREM trial, showing that maintenance therapy with rituximab reduces relapse rates compared with azathioprine among patients with ANCA-associated vasculitis (2:09).
12-11-2019 | ANCA-associated vasculitis | Video | Article